Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IL-2 in Advanced Melanoma After Anti-PD1 Failure
NCT02796352Phase 2Terminated
- Sponsor
- Ahmad Tarhini
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in melanoma, sponsored by Ahmad Tarhini. Started Sep 2016; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02796352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796352.